Mechanism by which chronic kidney disease causes cardiovascular disease and the measures to manage this phenomenon

Clinical and Experimental Nephrology

Volumn 15, Issue 5, 2011, Pages 627-633

  Kusano, Eiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cardiovascular disease; Chronic kidney disease; Endothelial progenitor cells; Indoxyl sulfate; Klotho gene

Indexed keywords

ALISKIREN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COUGHING; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; GENE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KLOTHO GENE; PATIENT PARTICIPATION; PRIMARY MEDICAL CARE; REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; GLOMERULAR FILTRATION RATE; GLUCURONIDASE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; PHYSICIANS, PRIMARY CARE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 80755190013     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0461-x     Document Type: Review

References (41)

1. Japanese Society of Nephrology, editors. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease. Tokyo: Tokyo Igakusha. 2009.
2. E Imai M Horio T Watanabe K Iseki K Yamagata S Hara, et al. 2009 Prevalence of chronic kidney disease in the Japanese general population Clin Exp Nephrol 13 631 632 10.1007/s10157-009-0238-7
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305.
4. T Ninomiya Y Kiyohara M Kubo Y Tanizaki Y Doi K Okubo, et al. 2005 Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study Kidney Int 68 228 236 15954912 10.1111/j.1523-1755.2005.00397.x (Pubitemid 43181380)
5. K Yamagata K Ishida T Sairenchi H Takahashi S Ohba T Shiigai, et al. 2007 Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study Kidney Int 71 2 159 166 17136030 10.1038/sj.ki.5002017 1:STN:280:DC%2BD2s%2FhslOjtg%3D%3D (Pubitemid 46094690)
6. JH Choi KL Kim W Huh B Kim J Byun W Suh J Sung ES Jeon HY Oh DK Kim 2004 Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure Arterioscler Thromb Vasc Biol 24 7 1246 1252 15155385 10.1161/01.ATV.0000133488.56221.4a 1:CAS:528: DC%2BD2cXlt1Wltbo%3D (Pubitemid 38880016)
7. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103(3):921-6 (Epub 2003 Oct 2). (Pubitemid 38129551)
8. T Eizawa Y Murakami K Matsui M Takahashi K Muroi E Kusano, et al. 2003 Circulating endothelial progenitor cells are reduced in hemodialysis patients Curr Med Res Opin 19 7 627 633 14606986 10.1185/030079903125002379 (Pubitemid 37288070)
9. H Yamamoto S Tsuruoka T Ioka H Ando C Ito E Kusano, et al. 2006 Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells Kidney Int 69 10 1780 1785 16612331 10.1038/sj.ki.5000340 1:CAS:528:DC%2BD28XksVGnt70%3D (Pubitemid 43739205)
10. T Nakamura Y Kawagoe T Matsuda Y Ueda N Shimada I Ebihara, et al. 2004 Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure Kidney Blood Press Res 27 2 121 126 15051932 10.1159/000077536 1:CAS:528:DC%2BD2cXjsF2kt7c%3D (Pubitemid 38594564)
11. K Taki Y Tsuruta T Niwa 2007 Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients Am J Nephrol 27 1 30 35 17215572 10.1159/000098542 1:CAS:528:DC%2BD2sXisFygsr4%3D (Pubitemid 46364538)
12. A Adijiang S Goto S Uramoto F Nishijima T Niwa 2008 Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats Nephrol Dial Transplant 23 6 1892 1901 18334529 10.1093/ndt/gfm861 1:CAS:528:DC%2BD1cXmtlClsbg%3D (Pubitemid 351768144)
13. H Fujii 2009 Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress Nephrol Dial Transplant 24 7 2089 2095 19188341 10.1093/ndt/gfp007 1:CAS:528:DC%2BD1MXnslKjsb4%3D
14. FC Barreto DV Barreto S Liabeuf N Meert G Glorieux M Temmar, et al. 2009 Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients Clin J Am Soc Nephrol 4 10 1551 1558 19696217 10.2215/CJN.03980609 1:CAS:528:DC%2BD1MXhtlGgur%2FJ
15. Masuda T, Murata M, Honma S, Iwazu Y, Kusano E, Asano Y et al. Sleep-disordered breathing predicts cardiovascular events and mortality in hemodialysis patients. Nephrol Dial Transplant. 2011.
16. E Shahar CW Whitney S Redline ET Lee AB Newman F Javier Nieto, et al. 2001 Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study Am J Respir Crit Care Med 163 19 25 11208620 1:STN:280:DC%2BD3MzgtVygsw%3D%3D (Pubitemid 32095247)
17. M Kuro-o Y Matsumura H Aizawa H Kawaguchi T Suga YI Nabeshima, et al. 1997 Mutation of the mouse klotho gene leads to a syndrome resembling ageing Nature 390 6655 45 51 9363890 10.1038/36285 1:CAS:528:DyaK2sXnt1Cnu70%3D (Pubitemid 27494749)
18. M Kuro-o 2010 Klotho Pflugers Arch 459 2 333 343 19730882 10.1007/s00424-009-0722-7 1:CAS:528:DC%2BC3cXisVSksA%3D%3D
19. SA Li M Watanabe H Yamada A Nagai M Kinuta K Takei 2004 Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice Cell Struct Funct 29 4 91 99 15665504 10.1247/csf.29.91 1:CAS:528:DC%2BD2MXht12rtrg%3D (Pubitemid 40260033)
20. PU Torres D Prié V Molina-Blétry L Beck C Silve G Friedlander 2007 Klotho: an antiaging protein involved in mineral and vitamin D metabolism Kidney Int 71 8 730 737 17332731 10.1038/sj.ki.5002163 (Pubitemid 46624027)
21. Haruna Y, Kashihara N, Satoh M, Tomita N, Namikoshi T et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci USA. 2007;104(7):2331-6 (Epub 2007 Feb 7). (Pubitemid 46391397)
22. Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro-O M, Huang CL. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci USA. 2008;105(28):9805-10. (Pubitemid 352031381)
23. SK Cha MC Hu H Kurosu M Kuro-o O Moe CL Huang 2009 Regulation of renal outer medullary potassium channel and renal K(+) excretion by Klotho Mol Pharmacol 76 1 38 46 19349416 10.1124/mol.109.055780 1:CAS:528: DC%2BD1MXos1amtrs%3D
24. H Kurosu M Yamamoto JD Clark JV Pastor A Nandi M Kuro-o, et al. 2005 Suppression of aging in mice by the hormone Klotho Science 309 5742 1829 1833 16123266 10.1126/science.1112766 1:CAS:528:DC%2BD2MXpvFCisb0%3D (Pubitemid 41325087)
25. H Liu MM Fergusson RM Castilho J Liu L Cao J Chen, et al. 2007 Augmented Wnt signaling in a mammalian model of accelerated aging Science 317 5839 803 806 17690294 10.1126/science.1143578 1:CAS:528:DC%2BD2sXptVWjt7s%3D (Pubitemid 47257917)
26. Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, Shiizaki K, Gotschall R, Schiavi S, Yorioka N, Takahashi M, Boothman DA, Kuro-O M. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem. 2011;286(10):8655-65.
27. S Bose S French FJ Evans F Joubert RS Balaban 2003 Metabolic network control of oxidative phosphorylation: multiple roles of inorganic phosphate J Biol Chem 278 40 39155 39165 12871940 10.1074/jbc.M306409200 1:CAS:528:DC%2BD3sXnslWjtLc%3D (Pubitemid 37221818)
28. JR Stubbs S Liu W Tang J Zhou Y Wang X Yao, et al. 2007 Role of hyperphosphatemia and 1, 25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice J Am Soc Nephrol 18 2116 2124 17554146 10.1681/ASN.2006121385 1:CAS:528:DC%2BD2sXotlWnur4%3D (Pubitemid 47041077)
29. M Ohnishi MS Razzaque 2010 Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging FASEB J 24 9 3562 3571 20418498 10.1096/fj.09-152488 1:CAS:528:DC%2BC3cXhtFGgt7%2FP
30. M Tonelli F Sacks M Pfeffer, et al. 2005 Relation between serumphosphate level and cardiovascular event rate in people with coronary disease Circulation 112 2627 2633 16246962 10.1161/CIRCULATIONAHA.105.553198 1:CAS:528: DC%2BD2MXhtFajtLvO (Pubitemid 41532599)
31. SK Ganesh AG Stack NW Levin, et al. 2001 Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients J Am Soc Nephrol 12 2131 2138 11562412 1:CAS:528:DC%2BD3MXnsFWiurk%3D (Pubitemid 32880350)
32. GL Bakris 2001 A practical approach to achieving recommended blood pressure goals in diabetic patients Arch Intern Med 161 22 2661 2667 11732930 10.1001/archinte.161.22.2661 1:STN:280:DC%2BD38%2FivVOnug%3D%3D (Pubitemid 33134841)
33. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K; Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007;72(12):1543-9. (Pubitemid 350199443)
34. Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Matsuoka H et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res. 2007;30(7):621-6. (Pubitemid 47278320)
35. T Nakamura T Sugaya Y Kawagoe T Suzuki Y Ueda H Koide, et al. 2007 Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease Am J Med Sci 333 6 321 326 17570983 10.1097/MAJ.0b013e318065c254 (Pubitemid 46945471)
36. ZH Israili WD Hall 1992 Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology Ann Intern Med 117 3 234 242 1616218 1:STN:280: DyaK38zht12nug%3D%3D
37. Y Morishita S Hanawa J Chinda O Iimura S Tsunematsu E Kusano 2011 Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension Hypertens Res 34 3 308 313 21124333 10.1038/hr.2010.238 1:CAS:528:DC%2BC3MXivVClsrw%3D
38. AJ Weinberg DH Zappe R Ramadugu MS Weinberg 2006 Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease J Hypertens Suppl 24 1 S95 S99 16601581 10.1097/01.hjh.0000220413.22482.36 1:CAS:528:DC%2BD28Xjt1Clt7o%3D (Pubitemid 44336830)
39. FH Bahlmann K de Groot O Mueller B Hertel H Haller D Fliser 2005 Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists Hypertension 45 4 526 529 15767470 10.1161/01.HYP.0000159191.98140.89 1:CAS:528:DC%2BD2MXisVGksr0%3D (Pubitemid 40411254)
40. K Matsuura N Hagiwara 2011 The pleiotropic effects of ARB in vascular endothelial progenitor cells Curr Vasc Pharmacol 9 2 153 157 21143169 10.2174/157016111794519345 1:CAS:528:DC%2BC3MXkslaisrw%3D
41. S Ito T Nagasawa M Abe T Mori 2009 Strain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk Hypertens Res 32 2 115 121 19262469 10.1038/hr.2008.27